For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
This kit is designed for the detection of binding between FcRn (neonatal Fc receptor) and human IgG using a homogeneous AlphaLISA assay (no wash steps). This assay can facilitate the design and development of antibody therapeutics using a competition assay format.
Human FcRn also known as Neonatal Fc receptor is a heterodimer of FCGRT (Fc Fragment of IgG Receptor and Transporter) and B2M (beta 2 microglobulin). Among several Fc receptors known to interact with IgG antibodies, FcRn plays a critical role in maintaining IgG homeostasis. After IgG binds to its target on the cell surface, it is pinocytozed to the endosome where FcRn binds to the antibodies at acidic pH (6.0) and recycles the antibodies back into circulation at physiological pH (7.4). The pH dependency of FcRn binding comes mostly from histidine residues His 310, His 435, and His 436 of IgG, which are protonated at pH 6 creating a strong interaction with the anionic pocket of FcRn; they are neutralized at pH 7.4 releasing IgG from FcRn. As a result, antibodies can be protected from lysosomal degradation, leading to enhanced in vivo stability and efficacy. Hence, profiling of FcRn binding is commonly required by regulatory agencies.
AlphaLISA detection of FcRn and IgG binding uses human IgG AlphaLISA® Acceptor beads and Streptavidin-coated Donor beads to capture biotinylated human Fc receptor. Donor beads and Acceptor beads come into proximity through IgG Fc fragment binding to FcRn. Excitation of the Donor beads provokes the release of singlet oxygen that triggers a cascade of energy transfer reactions in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||500 Assay Points|
Therapeutic antibodies have proven to be effective and safe treatments for various diseases, and understanding the binding of therapeutic antibodies to Fc receptors provides insights into their mechanism of action (MOA), efficacy, and safety. During early drug development, as potential therapeutic antibodies are selected and engineered, changes in Fc receptor affinity can be indicative of changes in effector function and serum half-life.
In this application note, we demonstrate how AlphaLISA® biochemical Fc receptor binding assays provide easy, robust methods to measure the binding of potential therapeutic antibodies to human Fc receptor proteins.